|Bid||17.08 x 2900|
|Ask||17.12 x 1800|
|Day's range||17.00 - 17.15|
|52-week range||15.30 - 20.00|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||32.35|
|Forward dividend & yield||0.85 (4.97%)|
|Ex-dividend date||29 Sep 2020|
|1y target est||N/A|
Shares of Molecular Templates (NASDAQ: MTEM) closed down 23.6% on Monday. The big drop came after the company announced that it was resuming full rights of engineered toxin bodies (ETB) candidate TAK-169 from Takeda (NYSE: TAK). Molecular Templates also said that it's discontinuing the development of MT-3724, another experimental ETB.
Novavax is likely to get authorization in the U.K. in coming weeks, and its vaccine manufacturing is scaling up amid unprecedented strains on materials and supplies.
Merck (MRK) is stepping up to help Johnson & Johnson (JNJ) produce its COVID-19 vaccine, which was authorized last weekend.